Objective Response Rate (ORR) in the liver was a secondary endpoint of the SIRFLOX study. SIR-Spheres® Y-90 resin microspheres in combination with first line chemotherapy, versus chemotherapy alone, showed a significant increase of 9.9% in ORR in the liver and a three-fold improvement in complete response rate (CR) in the liver.1

Response Rate in the liver


Patients who had a smaller liver tumor burden (≤12%) on study entry were more than six times as likely to experience a complete response or disappearance of all liver tumors following SIR-Spheres Y-90 resin microspheres compared to those who received only chemotherapy (11.3% vs.1.7%; p=0.003).2

 

bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
No statistically significant improvement of PFS at any site

1. van Hazel GA et al. J Clin Oncol 2016; 34: 1723–1731.
2. Heinemann V et al. ESMO WCGIC, Annals of Oncology 2016; 27 (Suppl 2): Abs. O-014.



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×